- Home
- LFS vs XGN Comparison
LFS vs XGN Comparison
Compare LFS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | XGN |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 138.9M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LFS | XGN |
|---|---|---|
| Price | $2.71 | $6.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 99.3K | ★ 295.4K |
| Earning Date | 05-20-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.71 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $77,480,718.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | $24.31 | ★ N/A |
| Revenue Growth | ★ 15.14 | 14.08 |
| 52 Week Low | $1.58 | $2.67 |
| 52 Week High | $12.49 | $12.23 |
Technical Indicators
Market Signals| Indicator | LFS | XGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.31 |
| Support Level | N/A | $5.84 |
| Resistance Level | N/A | $6.34 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 18.97 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.